Trials / Not Yet Recruiting
Not Yet RecruitingNCT07141095
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 17 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings. The participants will be treated with maribavir for up to 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | maribavir | Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient. |
Timeline
- Start date
- 2025-09-25
- Primary completion
- 2026-10-31
- Completion
- 2027-01-31
- First posted
- 2025-08-26
- Last updated
- 2025-08-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07141095. Inclusion in this directory is not an endorsement.